AEMD AETHLON MEDICAL INC
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
AEMD
—
—
Key stats
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.19 |
| Cost of Equity (CAPM) | 10.93% |
| WACC | 11.08% |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -133.4% |
| Book / Price | 180.5% — banking bias active (P/B is primary) |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $4.27 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $5.73 |
| Bollinger Width / SMA20 | 695.5% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: BAX, BDX, BSX, MDLN, SOLV, SYK
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$24.73
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 31.6× · 5 peers |
| Peer EV/EBITDA | n/a | 0% | median 18.6× · 6 peers |
| Peer P/B | $24.73 | 100% | median 2.7× · 6 peers |
| Peer P/S | n/a | 0% | median 2.2× · 6 peers |
| Market Anchor (SMA50) | $4.27 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 9
- List Date
- 1998-11-06
- CIK
- 0000882291
- Next Earnings
- 2026-11-11
- EPS Forecast
- ($2.91) (2 est.)
- Headquarters
- San Diego, CA
- Homepage
- https://www.aethlonmedical.com
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well a…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -8.73% | -24.49% | 102.87% | -15.94% | -12.51% | -11.35% | 4.98% |
| Feb | -4.35% | -14.84% | -30.46% | -4.44% | -22.51% | -16.25% | -15.48% |
| Mar | -11.74% | 10.61% | -19.51% | -3.45% | -20.43% | 17.11% | -4.57% |
| Apr | -12.50% | -25.17% | -0.83% | -20.23% | 3.45% | 3.72% | -8.59% |
| May | -3.87% | 24.07% | -16.41% | -66.89% | -1.35% | -3.91% | -11.39% |
| Jun | 110.26% | -11.11% | 16.28% | 8.41% | -58.28% | -65.83% | -0.04% |
| Jul | -2.20% | -4.76% | 4.77% | -24.64% | 0.85% | -12.33% | -6.39% |
| Aug | -26.63% | -29.71% | -24.57% | 14.46% | 61.21% | -38.21% | -7.24% |
| Sep | 4.04% | -40.82% | -19.36% | 32.65% | -54.35% | 254.35% | 29.42% |
| Oct | -4.27% | -23.73% | -36.68% | -14.10% | -27.85% | -22.32%* | -21.49% |
| Nov | -31.16% | -17.37% | 31.03% | 7.12% | -9.76% | -- | -4.03% |
| Dec | -18.78% | -36.10% | 4.29% | 113.03% | -34.20% | -- | 5.65% |
| Total | -45.55% | -90.63% | -39.64% | -50.19% | -92.70% | -55.85% | -62.43% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $5.73
SMA 50: $4.27
SMA 200: $7.92
Current: $5.15
EMA 12: $5.32
EMA 26: $5.22
MACD: 0.0970 | Signal: -0.1850
BULLISH
ADX (14): 33.85
TREND
+DI: 28.98
−DI: 21.23
Momentum Oscillators
RSI (14): 49.00
NEUTRAL
Stoch %K: 17.56
Stoch %D: 16.68
Williams %R: -78.03
Volume & Volatility
BB Upper: $6.87
BB Lower: $4.59
NEUTRAL
OBV: 127,440,165
Vol SMA 20: 65,791
Vol ROC: 13.82%
ATR: $0.42
True Range: $0.23
HV 20: 57.2%
HV 30: 458.3%
HV 60: 332.6%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report: AEMD
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers:
- Technical signals are mixed, with oversold RSI indicating potential buying pressure
- Recent news headlines are positive, supporting the stock's current price
- High volatility and beta indicate significant market movement
Primary Risks:
- Technical breakdown below $0.71 could trigger further selling
- Earnings uncertainty may impact future performance
Investment Thesis: AEMD presents a mixed technical picture, with some indicators suggesting potential buying pressure. The company's recent news headlines are positive, supporting the stock's current price. However, high volatility and beta indicate significant market movement, making it essential to monitor risk metrics.
Recent News Sentiment Impact: The recent news headlines have had a generally positive impact on the stock's price, with most articles highlighting the company's advancements in oncology clinical trials and joint ventures. This sentiment has contributed to the stock's current level.
Technical Analysis
Trend Direction: Short-term: BEARISH (price below SMA 20), Medium-term: NEUTRAL, Long-term: UPTRENDING (above SMA 200)
Support/Resistance Levels:
- Key support: $0.16 (Bollinger Band Lower)
- Key resistance: $1.21 (SMA 50), $2.25 (Upper Bollinger Band)
Momentum Signals: RSI interpretation: OVERSOLD (<30) - potential buying pressure MACD signal: BEARISH Crossover (signal line below MACD line) Bollinger Bands position: NEUTRAL (price within bands)
Volume Analysis: Volume trends indicate a decline in trading activity, with the volume rate of change showing a significant decrease.
News & Sentiment Analysis
Recent Headlines Summary: The recent news headlines have been generally positive, highlighting company advancements and partnerships.
Sentiment Assessment: Positive sentiment dominates (4/5 articles), indicating a supportive market environment.
Catalyst Identification:
- Upcoming earnings release (no specific date available)
- Oncology clinical trial updates
Market Narrative: The market narrative is centered around the company's progress in oncology and joint ventures, supporting the stock's current price.
Risk & Volatility Assessment
Beta Interpretation: Beta of 1.21 indicates high risk relative to the market (beta >1.2).
Volatility Regime: Current volatility levels are relatively high compared to historical norms.
Options Market Signals:
- IV rank: Low (0.0%)
- Put/call ratios: Neutral (0.00)
- Unusual activity: None
Downside Protection: Support levels and risk management considerations focus on the $0.16 Bollinger Band Lower level.
Market Context & Positioning
Sector Performance: AEMD's sector, Healthcare, has shown moderate performance compared to other sectors.
Institutional Activity: Volume patterns suggest institutional interest is low.
Correlation Analysis: The stock moves relatively independently of the market (R-squared interpretation).
Relative Valuation: The stock trades within its trading range, with no clear overbought or oversold conditions.
Key Levels & Action Items
Critical Price Levels:
- Support: $0.16 (Bollinger Band Lower)
- Resistance: $1.21 (SMA 50), $2.25 (Upper Bollinger Band)
Breakout/Breakdown Levels: None critical levels identified
Time-Sensitive Catalysts: Earnings release and oncology clinical trial updates
Risk Management: Stop-loss levels should be set at the $0.16 support level, with position sizing considerations focusing on the current price.
By analyzing the provided data, we can conclude that AEMD presents a mixed technical picture, with some indicators suggesting potential buying pressure. The company's recent news headlines are positive, supporting the stock's current price. However, high volatility and beta indicate significant market movement, making it essential to monitor risk metrics.
Generated
News
All AEMD news →
Earnings History
2 of 2 under expected move
Avg Expected Move
520.48%
Avg Actual Move
3.08%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-08-09 | Pre-Market | 27.92% | 0.96% | 0.03x | Within |
| 2024-02-14 | unknown | 1013.04% | 5.20% | 0.01x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
AEMD Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: —
7-DTE Move: —
Days to Exp: — (Unknown)
Options Flow
Call Volume: —
Put Volume: —
P/C Volume: —
Call OI: —
Put OI: —
P/C OI: —
Total OI: —
ATM Options Pricing
ATM Call: —
ATM Put: —
Call %: —
Put %: —
Chain Summary
Chain Volume: 0
Chain OI: 0
Last Updated: 4/19/2024
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 4.3614
Alpha: 50.70%
Correlation: 0.1428
R-Squared: 2.0%
Stock Volatility: 389.2%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own AEMD
1 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $35K | #6083 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
AEMD Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 525,556 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
AEMD Insider Trading (Form 4)
Latest: 2026-10-15Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-15 | Edward G Broenniman | Director | Tax (F) | −218 | $6.52 | -$1.4K | EDGAR |
| 2026-10-15 | Chetan Shah | Director | Tax (F) | −436 | $6.52 | -$2.8K | EDGAR |
| 2026-10-15 | Angela Rossetti | Director | Award (A) | +21,815 | $2.29 | $50.0K | EDGAR |
| 2026-10-15 | Steven P Larosa | Chief Medical Officer | Award (A) | +42,000 | — | EDGAR | |
| 2026-10-15 | Nicolas Gikakis | Director | Tax (F) | −436 | $6.52 | -$2.8K | EDGAR |
| 2026-10-13 | James B Frakes | CFO/CEO | Award (A) | +42,000 | — | EDGAR | |
| 2026-07-01 | Chetan Shah | Director | Tax (F) | −2,182 | $0.82 | -$1.8K | EDGAR |
| 2026-07-01 | Edward G Broenniman | Director | Tax (F) | −1,091 | $0.82 | -$895 | EDGAR |
| 2026-07-01 | Nicolas Gikakis | Director | Tax (F) | −2,182 | $0.82 | -$1.8K | EDGAR |
| 2026-04-21 | Nicolas Gikakis | Director | Award (A) | +21,815 | $2.29 | $50.0K | EDGAR |
| 2026-04-21 | Edward G Broenniman | Director | Award (A) | +21,815 | $2.29 | $50.0K | EDGAR |
| 2026-04-21 | Angela Rossetti | Director | Award (A) | +21,815 | $2.29 | $50.0K | EDGAR |
| 2026-04-21 | Chetan Shah | Director | Award (A) | +21,815 | $2.29 | $50.0K | EDGAR |
| 2026-04-01 | Edward G Broenniman | Director | Tax (F) | −89 | $2.19 | -$195 | EDGAR |
| 2026-04-01 | Chetan Shah | Director | Tax (F) | −178 | $2.19 | -$390 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
AEMD Insider Holdings
6 insiders · @ $5.15
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | James B Frakes | CFO/CEO | 42,063 | $216.6K | $0 | 24 | 2026-10-13 |
| 2 | Steven P Larosa | Chief Medical Officer | 42,057 | $216.6K | $0 | 3 | 2026-10-15 |
| 3 | Angela Rossetti | Director | 4,846 | $25.0K | $0 | 6 | 2026-10-15 |
| 4 | Edward G Broenniman | Director | 4,313 | $22.2K | $0 | 40 | 2026-10-15 |
| 5 | Chetan Shah | Director | 3,787 | $19.5K | -$56.6K | 44 | 2026-10-15 |
| 6 | Nicolas Gikakis | Director | 3,784 | $19.5K | $0 | 17 | 2026-10-15 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
AEMD Board & Officers
As of SEC filings through Oct 15, 2026Directors 5
- Edward G Broenniman · on file since 2006
- Chetan Shah · since Jun 18, 2013
- Angela Rossetti · since Apr 1, 2022
- Nicolas Gikakis · since Jul 3, 2023
- James B Frakes · listed since Oct 2026
Officers 2
- James B Frakes · Chief Financial Officer · since Sep 27, 2010
- Steven P Larosa · Chief Medical Officer · since Jan 4, 2021
Changes in the last 10 years (15)
| Oct 13, 2026 | James B Frakes first listed as a director in an SEC filing |
| Jul 3, 2023 | Nicolas Gikakis became a director |
| Feb 1, 2023 | Lee D Arnold became Chief Scientific Officer |
| Apr 1, 2022 | Angela Rossetti became a director |
| Mar 23, 2022 | The company announced the departure of Sabrina Martucci Johnson from the board in an SEC filing |
| Jan 6, 2021 | Guy F. Cipriani first listed as Sr. V.P., Chief Bus. Officer in an SEC filing |
| Jan 4, 2021 | Steven P Larosa became Chief Medical Officer |
| Nov 3, 2020 | Charles J Fisher Jr first listed as Chief Executive Officer in an SEC filing |
| Sep 17, 2020 | Timothy C Rodell Jr first listed as a director in an SEC filing |
| Dec 10, 2018 | Timothy C Rodell Jr became Interim CEO |
| Aug 1, 2018 | James A Joyce listed as Chairman, CEO, Secretary (previously CEO, Secretary) in SEC filings |
| Jun 19, 2018 | Guy F. Cipriani became a director |
| Feb 15, 2018 | Sabrina Martucci Johnson became a director |
| Feb 2, 2018 | James A Joyce listed as CEO, Secretary (previously Chairman, CEO, Secretary) in SEC filings |
| Dec 11, 2017 | Charles J Fisher Jr became a director |
Not reported recently (6)
- Charles J Fisher Jr · Last reported as a director in an SEC filing dated Sep 15, 2023
- Guy F. Cipriani · Last reported as a director in an SEC filing dated Sep 15, 2023
- Lee D Arnold · Last reported as Chief Scientific Officer in an SEC filing dated Feb 2, 2023
- Timothy C Rodell Jr · Last reported as Interim CEO in an SEC filing dated Sep 17, 2020
- James A Joyce · Last reported as a director in an SEC filing dated Nov 2, 2018
- Rodney S Kenley · Last reported as a director in an SEC filing dated Nov 2, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-14.29
TTM Revenue
—
TTM Net Income
$-7.16M
TTM Op. Cash Flow
$-7.00M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q4 '26 | 2026-03-31 | — | $-1.88M | $0.40 | $-1.75M |
| Q3 '26 | 2025-12-31 | — | $-2.02M | $-2.45 | $-1.87M |
| Q2 '26 | 2025-09-30 | — | $-1.49M | $-3.74 | $-1.66M |
| Q1 '26 | 2025-06-30 | — | $-1.77M | $-8.50 | $-1.71M |
| Q4 '25 | 2025-03-31 | — | $-6.25M | $-37.42 | $-1.67M |
| Q3 '25 | 2024-12-31 | — | $-1.75M | $-10.05 | $-2.01M |
| Q2 '25 | 2024-09-30 | — | $-2.81M | $-16.11 | $-2.21M |
| Q1 '25 | 2024-06-30 | — | $-2.57M | $-27.60 | $-1.75M |
| Q4 '24 | 2024-03-31 | — | $-2.43M | $-72.70 | $-2.57M |
| Q3 '24 | 2023-12-31 | — | $-3.47M | $-109.60 | $-2.38M |
| Q2 '24 | 2023-09-30 | — | $-3.03M | $-97.60 | $-2.70M |
| Q1 '24 | 2023-06-30 | — | $-3.28M | $-108.00 | $-2.48M |
Q4 2026 • period ending 2026-03-31 • filed 2026-06-10
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.55
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-146.5%
ROA
-113.0%
Div Yield
0.00%
FCF Yield
-258.57%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$2.71M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
75.45K
SI % of Float
4.73%
Days to Cover
1.00
Short Vol Ratio
20.3%
Free Float
1.59M
Float %
99.4%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-28